A. İNCEBIYIK Et Al. , "Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?," WIENER KLINISCHE WOCHENSCHRIFT , vol.128, 2016
İNCEBIYIK, A. Et Al. 2016. Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?. WIENER KLINISCHE WOCHENSCHRIFT , vol.128 .
İNCEBIYIK, A., Vural, M., CAMUZCUOĞLU, H., TAŞKIN, A., Camuzcuoglu, A., HİLALİ, N. G., ... AKSOY, N.(2016). Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?. WIENER KLINISCHE WOCHENSCHRIFT , vol.128.
İNCEBIYIK, ADNAN Et Al. "Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?," WIENER KLINISCHE WOCHENSCHRIFT , vol.128, 2016
İNCEBIYIK, ADNAN Et Al. "Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?." WIENER KLINISCHE WOCHENSCHRIFT , vol.128, 2016
İNCEBIYIK, A. Et Al. (2016) . "Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?." WIENER KLINISCHE WOCHENSCHRIFT , vol.128.
@article{article, author={ADNAN İNCEBIYIK Et Al. }, title={Can circulating M30 and M65 levels be beneficial markers in the diagnosis and management of patients with complete hydatidiform mole?}, journal={WIENER KLINISCHE WOCHENSCHRIFT}, year=2016}